Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.63 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.61 |
| ▸ | PGR | P06401 | 3/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.60 |
| ▸ | SHBG | P04278 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8903198 | 0.90 | NR3C1 (0.79) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| Fludrocortisone SCHEMBL13026141 | 0.88 | NR3C1 (1.00) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| SCHEMBL10429009 | 0.88 | NR3C1 (0.76) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| Fludrocortisone SCHEMBL4545 | 0.88 | NR3C1 (1.00) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| SCHEMBL10429011 | 0.88 | NR3C1 (0.76) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| Fludrocortisone SCHEMBL23975175 | 0.88 | NR3C1 (1.00) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| Fludrocortisone SCHEMBL4323075 | 0.88 | NR3C1 (1.00) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| Fludrocortisone SCHEMBL10598529 | 0.88 | NR3C1 (1.00) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| SCHEMBL11236450 | 0.88 | NR3C1 (0.76) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 | |
| Fludrocortisone SCHEMBL19327146 | 0.88 | NR3C1 (1.00) | NR3C1ALDH1A1MAPK1CYP2C19SERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109055546-A | Predict the method and DNA methylation marker of weightless bone loss cortisol Cortisol Upside Risk | 中国航天员科研训练中心 | 2018-12-21 | — | — | CN | claimed |
| US-20100047195-A1 | LIP BALM AND METHOD OF TREATING LIP CONDITIONS | ELBAUM DAVID | 2010-02-25 | — | — | US | claimed |
| WO-2009067234-A1 | COMPOSITION AND METHOD FOR TREATMENT OF ORAL INFLAMMATION AND ULCERATION | ZAHRA MOHAMMED (US) | 2009-05-28 | — | — | WO | claimed |
| WO-2008144592-A1 | LIP BALM AND METHOD OF TREATING LIP CONDITIONS | ELBAUM DAVID (US) | 2008-11-27 | — | — | WO | claimed |
| WO-2008118426-A1 | SPLIT DOSE CORTICOSTEROID THERAPY | COMBINATORX, INCORPORATED (US) | 2008-10-02 | — | — | WO | claimed |
| EP-1448205-A4 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
| EP-0872248-A2 | Pharmaceutical vehicles for reducing transdermal flux | Access Pharmaceuticals, Inc. (US) | 1998-10-21 | — | — | EP | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2025005885-A1 | CORTISOL SENSOR AND METHODS OF THEIR USE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-01-02 | — | — | WO | disclosed |
| EP-4434584-A2 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-0506207-A2 | Pharmaceutical vehicles for reducing transdermal flux | CHEMEX PHARMACEUTICALS, Inc. (US) | 1992-09-30 | — | — | EP | disclosed |
| US-4895727-A | Using water soluble zinc compound | CHEMEX PHARMACEUTICALS, INC. (US) | 1990-01-23 | — | — | US | disclosed |
| WO-1988003799-A1 | PHARMACEUTICAL VEHICLES FOR REDUCING TRANSDERMAL FLUX | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| EP-0221176-A4 | PHARMACEUTICAL VEHICLES FOR RECUCING TRANSDERMAL FLUX. | CHEMEX PHARMACEUTICALS INC (US) | 1988-01-25 | — | — | EP | disclosed |
| EP-0221176-A1 | PHARMACEUTICAL VEHICLES FOR RECUCING TRANSDERMAL FLUX. | CHEMEX PHARMACEUTICALS INC (US) | 1987-05-13 | — | — | EP | disclosed |
| WO-1986006586-A1 | PHARMACEUTICAL VEHICLES FOR RECUCING TRANSDERMAL FLUX | CHEMEX PHARMACEUTICALS, INC. (US) | 1986-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | NR3C1 1/4885ALDH1A1 3859/4885MAPK1 3238/4885 |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | NR3C1 1/4885ALDH1A1 3859/4885MAPK1 3238/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | NR3C1 4364/4885ALDH1A1 3637/4885MAPK1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.